MedTrace Logo

Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease

NCT03806478 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-07-27

No results posted yet for this study

Summary

This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.

Conditions

  • Dementia
  • Alzheimer Disease 1
  • Alzheimer Disease 2
  • Alzheimer Disease 3

Interventions

DRUG

APH-1105

The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.

OTHER

Placebo

The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug

Sponsors & Collaborators

  • Aphios

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-09-30
Completion
2024-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806478 on ClinicalTrials.gov